Skip to main content

Table 4 The change of CD4 count and HIV viral load in patients with HIV and concomitant CRC according to antiviral regimens (n = 66)

From: Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer

  

Baseline

M1

M3

M6

DTG/3TC/TDF (group I) n = 20

CD4 (cells/ul)

368.35 (195–980)

319.2 (164–624)

280.6 (146–578)

247.5 (150–456)

CD4/CD8 ratio

0.91 (0.19–2.87)

0.72 (0.22–2.22)

0.69 (0.3–1.64)

0.69 (0.5–1.01)

HIV viral load (copies/ml)

  ≤ 20

18

19

20

20

 20–1000

1

1

1

0

  > 1000

1

0

0

0

DTG/ABT (group II) n = 24

CD4 (cells/ul)

272.71 (83–757)

262.29 (108–494)

267.25 (210–513)

301 (167–337)

CD4/CD8 ratio

0.75 (0.14–2.86)

0.53 (0.11–0.8)

0.52 (0.2–1.4)

0.67 (0.2–1.5)

HIV viral load (copies/ml)

  ≤ 20

19

22

24

24

 20–1000

1

1

0

0

  > 1000

4

1

0

0

BIC/TAF/FTC (group III) n = 22

CD4 (cells/ul)

315.14 (85–980)

404.27 (111–479)

388.91 (86–577)

327.38 (82–612)

CD4/CD8 ratio

0.60 (0.08–1.68)

0.98 (0.09–2.86)

0.92 (0.21–1.7)

0.76 (0.2–1.29)

HIV viral load (copies/ml)

  ≤ 20

17

20

20

21

 20–1000

2

1

1

1

  > 1000

3

1

1

0

  1. CRC colorectal cancer
  2. DTG/3TC/TDF = dolutegravir/lamivudine/tenofovir
  3. DTG/ABT = dolutegravir/albuvirtide
  4. BIC/TAF/FTC = bictegravir/tenofovir alafenamide/emtricitabine
  5. M1 = the first month ± 1 week
  6. M3 = the third month ± 1 week
  7. M6 = the sixth month ± 1 week